Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 200

1.

Obesity Impacts Swelling of Ankle and Foot Joints in Early Rheumatoid Arthritis Patients.

Ranganath VK, Duffy EL, Garg VK, Woodworth T, Taylor M, Paulus HE, Altman RD, Elashoff DA.

J Clin Rheumatol. 2019 Apr;25(3):e8-e11. doi: 10.1097/RHU.0000000000000799.

PMID:
29683839
2.

Comprehensive appraisal of magnetic resonance imaging findings in sustained rheumatoid arthritis remission: a substudy.

Ranganath VK, Motamedi K, Haavardsholm EA, Maranian P, Elashoff D, McQueen F, Duffy EL, Bathon JM, Curtis JR, Chen W, Moreland L, Louie J, Amjadi S, O'Dell J, Cofield SS, St Clair EW, Bridges SL Jr, Paulus HE.

Arthritis Care Res (Hoboken). 2015 Jul;67(7):929-39. doi: 10.1002/acr.22541.

3.

Older age at rheumatoid arthritis onset and comorbidities correlate with less Health Assessment Questionnaire-Disability Index and Clinical Disease Activity Index response to etanercept in the RADIUS 2 registry.

Martin WJ, Shim M, Paulus HE, Chaudhari S, Feng J, Elashoff D, Hahn TJ, Ranganath VK; RADIUS Investigators.

J Clin Rheumatol. 2014 Sep;20(6):301-5. doi: 10.1097/RHU.0000000000000152.

4.

Examining radiographic outcomes over time.

Park GS, Wong WK, Khanna D, Gold RH, Paulus HE.

Rheumatol Int. 2014 Feb;34(2):271-9. doi: 10.1007/s00296-013-2879-9. Epub 2013 Oct 29.

PMID:
24166210
5.

Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis.

Ranganath VK, Maranian P, Elashoff DA, Woodworth T, Khanna D, Hahn T, Sarkisian C, Kremer JM, Furst DE, Paulus HE.

Rheumatology (Oxford). 2013 Oct;52(10):1809-17. doi: 10.1093/rheumatology/ket224. Epub 2013 Jun 27.

6.

Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial.

Navarro-Millán I, Charles-Schoeman C, Yang S, Bathon JM, Bridges SL Jr, Chen L, Cofield SS, Dell'Italia LJ, Moreland LW, O'Dell JR, Paulus HE, Curtis JR.

Arthritis Rheum. 2013 Jun;65(6):1430-8. doi: 10.1002/art.37916.

7.

Evaluation of test characteristics for outcome measures used in Raynaud's phenomenon clinical trials.

Gladue H, Maranian P, Paulus HE, Khanna D.

Arthritis Care Res (Hoboken). 2013 Apr;65(4):630-6. doi: 10.1002/acr.21858.

8.

Treatment of dyslipidemia in idiopathic inflammatory myositis: results of the International Myositis Assessment and Clinical Studies Group survey.

Charles-Schoeman C, Amjadi SS, Paulus HE; International Myositis Assessment and Clinical Studies Group.

Clin Rheumatol. 2012 Aug;31(8):1163-8. Epub 2012 Apr 21.

PMID:
22526479
9.

A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial.

Moreland LW, O'Dell JR, Paulus HE, Curtis JR, Bathon JM, St Clair EW, Bridges SL Jr, Zhang J, McVie T, Howard G, van der Heijde D, Cofield SS; TEAR Investigators.

Arthritis Rheum. 2012 Sep;64(9):2824-35. doi: 10.1002/art.34498.

10.

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.

Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O'Dell J, Winthrop KL, Beukelman T, Bridges SL Jr, Chatham WW, Paulus HE, Suarez-Almazor M, Bombardier C, Dougados M, Khanna D, King CM, Leong AL, Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain A, Volkmann ER, Agrawal H, Bae S, Mudano AS, Patkar NM, Saag KG.

Arthritis Care Res (Hoboken). 2012 May;64(5):625-39. doi: 10.1002/acr.21641. Review. No abstract available.

11.

Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis.

Charles-Schoeman C, Lee YY, Grijalva V, Amjadi S, FitzGerald J, Ranganath VK, Taylor M, McMahon M, Paulus HE, Reddy ST.

Ann Rheum Dis. 2012 Jul;71(7):1157-62. doi: 10.1136/annrheumdis-2011-200493. Epub 2012 Jan 20.

12.

An association study of disease activity score components and patient satisfaction with overall health for early RA patients on non-biologic DMARD therapy.

Kovalchik SA, Charles-Schoeman C, Khanna D, Paulus HE.

Rheumatol Int. 2012 Sep;32(9):2725-9. doi: 10.1007/s00296-011-2037-1. Epub 2011 Jul 30.

PMID:
21805175
13.

Patterns of radiographic outcomes in early, seropositive rheumatoid arthritis: a baseline analysis.

Park GS, Wong WK, Elashoff DA, Khanna D, Gold RH, Paulus HE.

Contemp Clin Trials. 2011 Mar;32(2):160-8. doi: 10.1016/j.cct.2010.11.009. Epub 2010 Nov 13.

PMID:
21078417
14.

Disease progression and treatment responses in a prospective DMARD-naive seropositive early rheumatoid arthritis cohort: does gender matter?

Jawaheer D, Maranian P, Park G, Lahiff M, Amjadi SS, Paulus HE.

J Rheumatol. 2010 Dec;37(12):2475-85. doi: 10.3899/jrheum.091432. Epub 2010 Oct 1.

15.

Remission in rheumatoid arthritis.

Shammas RM, Ranganath VK, Paulus HE.

Curr Rheumatol Rep. 2010 Oct;12(5):355-62. doi: 10.1007/s11926-010-0121-2. Review.

16.

A functional RANKL polymorphism associated with younger age at onset of rheumatoid arthritis.

Tan W, Wu H, Zhao J, Derber LA, Lee DM, Shadick NA, Conn DL, Smith EA, Gersuk VH, Nepom GT, Moreland LW, Furst DE, Thompson SD, Jonas BL, Holers VM, Glass DN, Chen PP, Bridges SL Jr, Weinblatt ME, Paulus HE, Tsao BP.

Arthritis Rheum. 2010 Oct;62(10):2864-75. doi: 10.1002/art.27589.

17.

Equivalent responses to disease-modifying antirheumatic drugs initiated at any time during the first 15 months after symptom onset in patients with seropositive rheumatoid arthritis.

Weng HH, Ranganath VK, Khanna D, Oh M, Furst DE, Park GS, Elashoff DA, Sharp JT, Gold RH, Peter JB, Paulus HE; Western Consortium of Practicing Rheumatologists.

J Rheumatol. 2010 Mar;37(3):550-7. doi: 10.3899/jrheum.090818. Epub 2010 Jan 28.

18.

Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis.

Charles-Schoeman C, Watanabe J, Lee YY, Furst DE, Amjadi S, Elashoff D, Park G, McMahon M, Paulus HE, Fogelman AM, Reddy ST.

Arthritis Rheum. 2009 Oct;60(10):2870-9. doi: 10.1002/art.24802.

19.

Validating and assessing the sensitivity of the Health Assessment Questionnaire-Disability Index-derived Short Form-6D in patients with early aggressive rheumatoid arthritis.

Amjadi SS, Maranian PM, Paulus HE, Kaplan RM, Ranganath VK, Furst DE, Khanna PP, Khanna D; Western Consortium of Practicing Rheumatologists.

J Rheumatol. 2009 Jun;36(6):1150-7. doi: 10.3899/jrheum.080959. Epub 2009 Apr 15.

20.

Functional improvement after patients with rheumatoid arthritis start a new disease modifying antirheumatic drug (DMARD) associated with frequent changes in DMARD: the CORRONA database.

Ranganath VK, Paulus HE, Onofrei A, Khanna D, Reed G, Elashoff DA, Kremer JM, Furst DE.

J Rheumatol. 2008 Oct;35(10):1966-71. Epub 2008 Sep 1.

21.

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, Mudano A, Pisu M, Elkins-Melton M, Outman R, Allison JJ, Suarez Almazor M, Bridges SL Jr, Chatham WW, Hochberg M, MacLean C, Mikuls T, Moreland LW, O'Dell J, Turkiewicz AM, Furst DE; American College of Rheumatology.

Arthritis Rheum. 2008 Jun 15;59(6):762-84. doi: 10.1002/art.23721. No abstract available.

22.

Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study.

Charles-Schoeman C, Khanna D, Furst DE, McMahon M, Reddy ST, Fogelman AM, Paulus HE, Park GS, Gong T, Ansell BJ.

J Rheumatol. 2007 Jul;34(7):1459-64. Epub 2007 Jun 1.

PMID:
17552046
23.

Assessment of American College of Rheumatology quality criteria for rheumatoid arthritis in a pre-quality criteria patient cohort.

Kahn KL, Maclean CH, Wong AL, Rubenstein LZ, Liu H, Fitzpatrick DM, Harker JO, Chen WP, Traina SB, Mittman BS, Hahn BH, Paulus HE.

Arthritis Rheum. 2007 Jun 15;57(5):707-15.

24.

Comparison of composite measures of disease activity in an early seropositive rheumatoid arthritis cohort.

Ranganath VK, Yoon J, Khanna D, Park GS, Furst DE, Elashoff DA, Jawaheer D, Sharp JT, Gold RH, Keystone EC, Paulus HE; Western Consortium of Practicing Rheumatologists.

Ann Rheum Dis. 2007 Dec;66(12):1633-40. Epub 2007 May 1.

25.

A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases.

Weisman MH, Paulus HE, Burch FX, Kivitz AJ, Fierer J, Dunn M, Kerr DR, Tsuji W, Baumgartner SW.

Rheumatology (Oxford). 2007 Jul;46(7):1122-5. Epub 2007 Apr 29.

PMID:
17470434
26.

Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort.

Khanna D, Oh M, Furst DE, Ranganath V, Gold RH, Sharp JT, Park GS, Keystone EC, Paulus HE; Western Consortium of Practicing Rheumatologists.

Arthritis Rheum. 2007 Apr 15;57(3):440-7.

27.

Classifying radiographic progression status in early rheumatoid arthritis patients using propensity scores to adjust for baseline differences.

Park GS, Wong WK, Oh M, Khanna D, Gold RH, Sharp JT, Paulus HE.

Stat Methods Med Res. 2007 Feb;16(1):13-29.

PMID:
17338292
28.

The complexity of care for patients with rheumatoid arthritis: metrics for better understanding chronic disease care.

Kahn KL, MacLean CH, Liu H, Rubenstein LZ, Wong AL, Harker JO, Chen WP, Fitzpatrick DM, Bulpitt KJ, Traina SB, Mittman BS, Hahn BH, Paulus HE.

Med Care. 2007 Jan;45(1):55-65.

PMID:
17279021
29.

Application of explicit process of care measurement to rheumatoid arthritis: Moving from evidence to practice.

Kahn KL, MacLean CH, Liu H, Rubenstein LZ, Wong AL, Harker JO, Chen WP, Fitzpatrick DM, Bulpitt KJ, Traina SB, Mittman BS, Hahn BH, Paulus HE.

Arthritis Rheum. 2006 Dec 15;55(6):884-91.

30.

Development and validation of the revised Cedars-Sinai health-related quality of life for rheumatoid arthritis instrument.

Chiou CF, Sherbourne CD, Cornelio I, Lubeck DP, Paulus HE, Dylan M, Chang CH, Weisman MH.

Arthritis Rheum. 2006 Dec 15;55(6):856-63.

31.

ACR remission criteria and response criteria.

Ranganath VK, Khanna D, Paulus HE.

Clin Exp Rheumatol. 2006 Nov-Dec;24(6 Suppl 43):S-14-21. Review.

PMID:
17083757
33.

Single-factor scoring validation for the Health Assessment Questionnaire-Disability Index (HAQ-DI) in patients with systemic sclerosis and comparison with early rheumatoid arthritis patients.

Cole JC, Khanna D, Clements PJ, Seibold JR, Tashkin DP, Paulus HE, Irwin MR, Motivala SJ, Furst DE.

Qual Life Res. 2006 Oct;15(8):1383-94. Epub 2006 Jul 7.

PMID:
16826439
34.

Patient's ethnicity does not influence utilization of effective therapies in rheumatoid arthritis.

Ang DC, Paulus HE, Louie JS.

J Rheumatol. 2006 May;33(5):870-8.

PMID:
16652419
35.

Association of tumor necrosis factor alpha polymorphism, but not the shared epitope, with increased radiographic progression in a seropositive rheumatoid arthritis inception cohort.

Khanna D, Wu H, Park G, Gersuk V, Gold RH, Nepom GT, Wong WK, Sharp JT, Reed EF, Paulus HE, Tsao BP; Western Consortium of Practicing Rheumatologists.

Arthritis Rheum. 2006 Apr;54(4):1105-16.

36.

Revalidation of the original Cedars-Sinai health-related quality of life in rheumatoid arthritis questionnaire.

Chiou CF, Sherbourne CD, Cornelio I, Lubeck DP, Paulus HE, Dylan M, Weisman M.

J Rheumatol. 2006 Feb;33(2):256-62.

PMID:
16465655
37.

Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry.

Weaver AL, Lautzenheiser RL, Schiff MH, Gibofsky A, Perruquet JL, Luetkemeyer J, Paulus HE, Xia HA, Leff JA; RADIUS Investigators.

Curr Med Res Opin. 2006 Jan;22(1):185-98.

PMID:
16393444
38.

Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study.

Gibofsky A, Palmer WR, Goldman JA, Lautzenheiser RL, Markenson JA, Weaver A, Schiff MH, Keystone EC, Paulus HE, Harrison MJ, Whitmore JB, Leff JA.

Curr Med Res Opin. 2006 Jan;22(1):169-83.

PMID:
16393443
39.

Reduction of the efficacy of methotrexate by the use of folic acid: post hoc analysis from two randomized controlled studies.

Khanna D, Park GS, Paulus HE, Simpson KM, Elashoff D, Cohen SB, Emery P, Dorrier C, Furst DE.

Arthritis Rheum. 2005 Oct;52(10):3030-8.

40.

Validation of single-factor structure and scoring protocol for the Health Assessment Questionnaire-Disability Index.

Cole JC, Motivala SJ, Khanna D, Lee JY, Paulus HE, Irwin MR.

Arthritis Rheum. 2005 Aug 15;53(4):536-42.

41.

Increased radiographic damage scores at the onset of seropositive rheumatoid arthritis in older patients are associated with osteoarthritis of the hands, but not with more rapid progression of damage.

Khanna D, Ranganath VK, Fitzgerald J, Park GS, Altman RD, Elashoff D, Gold RH, Sharp JT, Furst DE, Paulus HE; Western Consortium of Practicing Rheumatologists.

Arthritis Rheum. 2005 Aug;52(8):2284-92.

42.

Age adjustment corrects for apparent differences in erythrocyte sedimentation rate and C-reactive protein values at the onset of seropositive rheumatoid arthritis in younger and older patients.

Ranganath VK, Elashoff DA, Khanna D, Park G, Peter JB, Paulus HE; Western consortium of practicing rhuemotologists.

J Rheumatol. 2005 Jun;32(6):1040-2.

PMID:
15940764
43.

Interaction between RANKL and HLA-DRB1 genotypes may contribute to younger age at onset of seropositive rheumatoid arthritis in an inception cohort.

Wu H, Khanna D, Park G, Gersuk V, Nepom GT, Wong WK, Paulus HE, Tsao BP.

Arthritis Rheum. 2004 Oct;50(10):3093-103.

44.

Dating the "window of therapeutic opportunity" in early rheumatoid arthritis: accuracy of patient recall of arthritis symptom onset.

Amjadi S, Khanna D, Park GS, Bulpitt KJ, Wong WK, Paulus HE.

J Rheumatol. 2004 Sep;31(9):1686-92. Erratum in: J Rheumatol. 2011 Jan;38(1):183. Amjadi-Begvand, Sogol [corrected to Amjadi, Sogol].

PMID:
15338485
45.

Development and evaluation of a patient self-report case-finding method for rheumatoid arthritis.

Wong AL, Harker JO, Mittman BS, Levy GD, Bulpitt KJ, Colburn KK, Liu H, Kahn KL, Hahn BH, Paulus HE, Rubenstein LZ.

Semin Arthritis Rheum. 2004 Aug;34(1):484-99.

PMID:
15305246
46.

Development and validation of Cedars-Sinai Health-Related Quality of Life in Rheumatoid Arthritis (CSHQ-RA) short form instrument.

Chiou CF, Sherbourne CD, Ofman J, Lee M, Lubeck DP, Paulus HE, Weisman M.

Arthritis Rheum. 2004 Jun 15;51(3):358-64.

47.

Is erythrocyte sedimentation rate the preferable measure of the acute phase response in rheumatoid arthritis?

Paulus HE, Brahn E.

J Rheumatol. 2004 May;31(5):838-40. Review. No abstract available.

PMID:
15124238
48.

Case finding for population-based studies of rheumatoid arthritis: comparison of patient self-reported ACR criteria-based algorithms to physician-implicit review for diagnosis of rheumatoid arthritis.

Liu H, Harker JO, Wong AL, Maclean CH, Bulpitt KJ, Mittman BS, Fitzgerald J, Grossman J, Rubenstein LZ, Hahn B, Paulus HE, Kahn KL.

Semin Arthritis Rheum. 2004 Apr;33(5):302-10.

PMID:
15079761
49.

Classifying structural joint damage in rheumatoid arthritis as progressive or nonprogressive using a composite definition of joint radiographic change: a preliminary proposal.

Paulus HE, Oh M, Sharp JT, Gold RH, Wong WK, Park GS, Bulpitt KJ; Western Consortium of Practicing Rheumatologists.

Arthritis Rheum. 2004 Apr;50(4):1083-96.

50.

Patient retention and hand-wrist radiograph progression of rheumatoid arthritis during a 3-year prospective study that prohibited disease modifying antirheumatic drugs.

Paulus HE, Di Primeo D, Sharp JT, Genant HK, Weissman BN, Weisman MH, Sanda M; Long-Term Etodolac Study Investigators.

J Rheumatol. 2004 Mar;31(3):470-81.

PMID:
14994390

Supplemental Content

Loading ...
Support Center